LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

20.46 -1.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.3

Максимум

21.2

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+95.54% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	42M 1.9B
Предишно отваряне	22.24
Предишно затваряне	20.46

Настроения в новините

By Acuity

50%

162 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2026 г., 22:54 ч. UTC

Печалби

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.05.2026 г., 23:17 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13.05.2026 г., 23:16 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13.05.2026 г., 23:15 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13.05.2026 г., 23:14 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Печалби

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13.05.2026 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13.05.2026 г., 22:24 ч. UTC

Печалби

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Organic Revenue Growth 25%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Revenue Growth 47%>XRO.AU

13.05.2026 г., 22:22 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13.05.2026 г., 22:18 ч. UTC

Печалби

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13.05.2026 г., 22:16 ч. UTC

Печалби

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13.05.2026 г., 22:13 ч. UTC

Печалби

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13.05.2026 г., 22:12 ч. UTC

Печалби

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero Did Not Declare a Dividend>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13.05.2026 г., 22:09 ч. UTC

Печалби

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13.05.2026 г., 22:00 ч. UTC

Печалби

Cisco to Shed Jobs for All-In AI Push -- Update

13.05.2026 г., 21:11 ч. UTC

Печалби

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

95.54% нагоре

12-месечна прогноза

Среден 39.91 USD 95.54%

Висок 57 USD

Нисък 29 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

162 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.